Can You Have Scleroderma Without Skin Changes?
At a Glance
Systemic sclerosis sine scleroderma (ssSSc) is a recognized subtype of scleroderma where patients develop internal organ damage, blood vessel changes, and autoantibodies without the classic skin thickening. Regular, proactive screening of the lungs, heart, and digestive tract is critical.
It is completely understandable to be confused by a diagnosis of scleroderma when your skin is perfectly fine. The word “scleroderma” literally translates to “hard skin,” which makes a diagnosis without skin thickening sound like a contradiction. However, you have a specific, recognized subtype of the disease called systemic sclerosis sine scleroderma (ssSSc). In medicine, “sine” means “without.” This diagnosis means you have the internal features of systemic sclerosis—such as organ involvement, vascular changes, and specific autoantibodies—but without the classic skin thickening [1][2].
Why the Name Doesn’t Always Fit
Historically, systemic sclerosis was named for its most visible and obvious symptom: thick, tight skin. But over the years, doctors have learned that systemic sclerosis is not just a skin disease. It is a complex autoimmune condition driven by three main problems: an overactive immune system, damage to small blood vessels, and fibrosis (the overproduction of collagen that causes scarring) [1].
In most patients, this scarring process affects the skin. But in systemic sclerosis sine scleroderma, the fibrosis skips the skin entirely and only targets the internal organs [3][4]. You still have the disease, but your immune system is expressing it differently. A common question patients ask is whether their skin will eventually harden. While a small percentage of people with this subtype may develop some mild skin thickening years later, many never do. Regardless, your internal health remains the most important focus.
How the Diagnosis is Made
Because there are no visible skin changes, systemic sclerosis sine scleroderma can be challenging for doctors to diagnose [3]. The diagnosis is usually confirmed when a patient has a combination of the following:
- Internal Organ Involvement: Common issues include gastroesophageal reflux disease (GERD) or difficulty swallowing, as well as lower digestive issues like bloating or altered bowel habits. More severely, it can involve scarring in the lungs (interstitial lung disease, or ILD), and high blood pressure in the lungs (pulmonary arterial hypertension) [1][5].
- Raynaud’s Phenomenon: The fingers or toes turning white, blue, and red in response to cold or stress. This is extremely common in all forms of systemic sclerosis [4].
- Nailfold Capillaroscopy: A painless test where your rheumatologist looks at the base of your fingernails under a magnifying device to check for abnormal or damaged blood vessels [4].
- Autoantibodies: Blood tests that reveal specific scleroderma-related antibodies. The anti-centromere antibody (ACA) is the most common in the “sine” subtype, though others like anti-Scl-70 or anti-RNA polymerase III can also be found [5][4]. You do not need to memorize these names, but you can check them against your own lab reports.
The Importance of Proactive Monitoring
Even though your skin is unaffected, systemic sclerosis sine scleroderma requires the exact same level of medical vigilance as other types of scleroderma. The lack of skin involvement does not mean your internal organs are protected [6]. In fact, lung scarring (ILD) is a frequent complication in patients with this subtype [1][7].
Because you cannot see the internal changes happening, regular proactive screening is essential. Your rheumatologist—often working alongside specialists like pulmonologists (lung doctors) and gastroenterologists (GI doctors)—should monitor your heart, lungs, kidneys, and digestive tract continuously to catch any internal changes early [8][9]. This typically involves regular breathing tests (pulmonary function tests), echocardiograms (ultrasounds of the heart), and routine blood pressure checks to monitor your kidney health [8][10].
While the outlook for adults with systemic sclerosis sine scleroderma is often better than for those with widespread (diffuse) skin involvement, the potential for internal organ damage makes expert, ongoing care absolutely critical [1][11].
Common questions in this guide
What does 'sine scleroderma' mean?
Will my skin eventually harden if I have systemic sclerosis sine scleroderma?
How do doctors diagnose scleroderma if I don't have skin changes?
What internal organs are most affected by systemic sclerosis sine scleroderma?
Do I still need medical monitoring if my skin is completely fine?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my specific autoantibodies, which internal organs are most at risk and require the closest monitoring?
- 2.How frequently should I be getting pulmonary function tests (PFTs) and echocardiograms?
- 3.What early warning signs of lung or kidney involvement should I be looking out for at home?
- 4.Do I need to regularly track my blood pressure at home to monitor for kidney-related complications?
- 5.Which other specialists, such as a pulmonologist or gastroenterologist, should be part of my core care team?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A, Huang S, Carreira PE, et al.
JAMA dermatology 2023; (159(8)):837-847 doi:10.1001/jamadermatol.2023.1729.
PMID: 37378994 - 2
A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma.
Lee CM, Girnita D, Sharma A, et al.
Case reports in rheumatology 2016; (2016()):8536341 doi:10.1155/2016/8536341.
PMID: 27559487 - 3
Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology.
De Angelis R, Ferri C, Giuggioli D, et al.
RMD open 2023; (9(1)) doi:10.1136/rmdopen-2022-002890.
PMID: 36868782 - 4
Systemic Sclerosis Sine Scleroderma in Mexican Patients. Case Reports.
Vera-Lastra O, Sauceda-Casas CA, Domínguez MDPC, et al.
Reumatologia clinica 2018; (14(4)):230-232 doi:10.1016/j.reuma.2016.11.004.
PMID: 28065485 - 5
Scleroderma Renal Crisis in a Systemic Sclerosis With Anti-PM/Scl Antibodies.
Jacquier M, Mousson C, Rebibou JM, et al.
Kidney international reports 2019; (4(10)):1499-1502 doi:10.1016/j.ekir.2019.07.002.
PMID: 31701063 - 6
Systemic sclerosis sine scleroderma with atypical clinical course: a rare case report.
Samha R, Ghaddar SA, Raya M, Alhadi SA
Annals of medicine and surgery (2012) 2023; (85(11)):5656-5661 doi:10.1097/MS9.0000000000001266.
PMID: 37915647 - 7
Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D, Ortego-Centeno N, Callejas JL, et al.
Rheumatology international 2018; (38(3)):363-374 doi:10.1007/s00296-017-3916-x.
PMID: 29322341 - 8
Systemic sclerosis.
Volkmann ER, Andréasson K, Smith V
Lancet (London, England) 2023; (401(10373)):304-318 doi:10.1016/S0140-6736(22)01692-0.
PMID: 36442487 - 9
Screening for pulmonary arterial hypertension in systemic sclerosis.
Weatherald J, Montani D, Jevnikar M, et al.
European respiratory review : an official journal of the European Respiratory Society 2019; (28(153)) doi:10.1183/16000617.0023-2019.
PMID: 31366460 - 10
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
Zanatta E, Huscher D, Ortolan A, et al.
Rheumatology (Oxford, England) 2022; (61(12)):4786-4796 doi:10.1093/rheumatology/keac188.
PMID: 35348643 - 11
Sine scleroderma, limited cutaneous, and diffused cutaneous systemic sclerosis survival and predictors of mortality.
De Almeida Chaves S, Porel T, Mounié M, et al.
Arthritis research & therapy 2021; (23(1)):295 doi:10.1186/s13075-021-02672-y.
PMID: 34876194
This page provides educational information about systemic sclerosis sine scleroderma. It does not replace professional medical advice, so please consult your rheumatologist about your specific diagnosis and screening schedule.
Get notified when new evidence is published on Scleroderma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.